Gritstone bio, Inc. (GRTS)

1.9500 -0.0300 (-1.52%) At close: 04:00PM EDT

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 193

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.	Co-Founder, Pres, CEO & Director	873.68k	N/A	1967
Mr. Erin E. Jones M.S.	Exec. VP & COO	537.38k	N/A	1972
Ms. Vassiliki Economides	Exec. VP & CFO	N/A	N/A	1981
Mr. James Cho	Chief Accounting Officer	N/A	N/A	N/A
Mr. Rahsaan W. Thompson J.D.	Exec. VP & Gen. Counsel	N/A	N/A	1971
Ms. Stacy Proctor	Sr. VP & Head of People	N/A	N/A	N/A
Dr. Matthew Hawryluk	Exec. VP & Chief Bus. Officer	N/A	N/A	1978
Dr. Karin Jooss Ph.D.	Exec. VP and Head of R&D	N/A	N/A	1965
Mr. Vijay Yabannavar Ph.D.	Exec. VP & Chief Technical Devel. Officer	N/A	N/A	1962

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone bio, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.